menin inhibitor

Ask MedXY AI

Latest news

Tag

Hematology-Oncologymenin inhibitorNPM1-mutated AML

Ziftomenib Shows Clinically Meaningful Activity in Heavily Pretreated NPM1‑Mutated AML — A Targeted Option for a Molecularly Defined Relapse Population

By MedXY|Dec 12, 2025

In the phase II registration cohort of KOMET‑001, oral menin inhibitor ziftomenib achieved a CR/CRh rate of 22% (61% MRD negativity) and an ORR of 33% in relapsed/refractory NPM1‑mutated AML with manageable toxicity, supporting further stud

$FDA Clears Second Menin Inhibitor — Ziftomenib (Komzifti) for Relapsed/Refractory NPM1‑Mutated AML$

Hematology-Oncologymenin inhibitorNPM1-mutated AML

FDA Clears Second Menin Inhibitor — Ziftomenib (Komzifti) for Relapsed/Refractory NPM1‑Mutated AML

By MedXY|Nov 13, 2025

Ziftomenib is FDA-approved for adults with relapsed/refractory NPM1‑mutated AML based on single‑arm KOMET‑001 data showing a 22% remission rate and manageable toxicity including differentiation syndrome; randomized trials are planned to def

$Revumenib: A New Menin Inhibitor Offering Hope for NPM1-Mutated Relapsed/Refractory AML$

Hematology-Oncologymenin inhibitorNPM1-mutated AML

Revumenib: A New Menin Inhibitor Offering Hope for NPM1-Mutated Relapsed/Refractory AML

By MedXY|Oct 5, 2025

The phase 2 AUGMENT-101 study demonstrates that revumenib, a selective menin inhibitor, induces meaningful remissions and enables stem cell transplantation in heavily pretreated, older patients with relapsed or refractory NPM1-mutated AML,